CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM …
Jetzt den vollständigen Artikel lesen